Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells.

Azarenko O, Smiyun G, Mah J, Wilson L, Jordan MA.

Mol Cancer Ther. 2014 Aug;13(8):2092-103. doi: 10.1158/1535-7163.MCT-14-0265. Epub 2014 Jun 30.

2.

βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.

Smiyun G, Azarenko O, Miller H, Rifkind A, LaPointe NE, Wilson L, Jordan MA.

Cancer Chemother Pharmacol. 2017 Jul;80(1):151-164. doi: 10.1007/s00280-017-3345-2. Epub 2017 May 31.

PMID:
28567478
3.

Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.

Vrignaud P, Sémiond D, Lejeune P, Bouchard H, Calvet L, Combeau C, Riou JF, Commerçon A, Lavelle F, Bissery MC.

Clin Cancer Res. 2013 Jun 1;19(11):2973-83. doi: 10.1158/1078-0432.CCR-12-3146. Epub 2013 Apr 15.

4.

Mechanisms of resistance to cabazitaxel.

Duran GE, Wang YC, Francisco EB, Rose JC, Martinez FJ, Coller J, Brassard D, Vrignaud P, Sikic BI.

Mol Cancer Ther. 2015 Jan;14(1):193-201. doi: 10.1158/1535-7163.MCT-14-0155. Epub 2014 Nov 21.

5.

Preclinical profile of cabazitaxel.

Vrignaud P, Semiond D, Benning V, Beys E, Bouchard H, Gupta S.

Drug Des Devel Ther. 2014 Oct 13;8:1851-67. doi: 10.2147/DDDT.S64940. eCollection 2014. Review.

6.

Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin.

Gan PP, McCarroll JA, Po'uha ST, Kamath K, Jordan MA, Kavallaris M.

Mol Cancer Ther. 2010 May;9(5):1339-48. doi: 10.1158/1535-7163.MCT-09-0679. Epub 2010 May 4.

7.

2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules.

Kamath K, Okouneva T, Larson G, Panda D, Wilson L, Jordan MA.

Mol Cancer Ther. 2006 Sep;5(9):2225-33.

8.

An antitubulin agent BCFMT inhibits proliferation of cancer cells and induces cell death by inhibiting microtubule dynamics.

Rai A, Surolia A, Panda D.

PLoS One. 2012;7(8):e44311. doi: 10.1371/journal.pone.0044311. Epub 2012 Aug 31.

9.

Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.

Wang RC, Chen X, Parissenti AM, Joy AA, Tuszynski J, Brindley DN, Wang Z.

PLoS One. 2017 Aug 7;12(8):e0182400. doi: 10.1371/journal.pone.0182400. eCollection 2017.

10.

Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.

Reynolds CP, Kang MH, Maris JM, Kolb EA, Gorlick R, Wu J, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2015 Nov;62(11):1897-905. doi: 10.1002/pbc.25611. Epub 2015 Jul 7.

11.

Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer?

Mita AC, Figlin R, Mita MM.

Clin Cancer Res. 2012 Dec 15;18(24):6574-9. doi: 10.1158/1078-0432.CCR-12-1584. Epub 2012 Oct 22.

13.

Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis.

Hernández-Vargas H, Palacios J, Moreno-Bueno G.

Oncogene. 2007 May 3;26(20):2902-13. Epub 2006 Nov 13.

PMID:
17099726
14.

Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.

Sampath D, Greenberger LM, Beyer C, Hari M, Liu H, Baxter M, Yang S, Rios C, Discafani C.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3459-69.

15.

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.

van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM.

Eur J Cancer. 2013 Dec;49(18):3821-30. doi: 10.1016/j.ejca.2013.09.026. Epub 2013 Oct 24.

PMID:
24200698
16.
17.

Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.

Wang H, Vo T, Hajar A, Li S, Chen X, Parissenti AM, Brindley DN, Wang Z.

BMC Cancer. 2014 Jan 22;14:37. doi: 10.1186/1471-2407-14-37.

18.

Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane.

Azarenko O, Okouneva T, Singletary KW, Jordan MA, Wilson L.

Carcinogenesis. 2008 Dec;29(12):2360-8. doi: 10.1093/carcin/bgn241. Epub 2008 Oct 23.

19.
20.

Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.

de Leeuw R, Berman-Booty LD, Schiewer MJ, Ciment SJ, Den RB, Dicker AP, Kelly WK, Trabulsi EJ, Lallas CD, Gomella LG, Knudsen KE.

Clin Cancer Res. 2015 Feb 15;21(4):795-807. doi: 10.1158/1078-0432.CCR-14-1358.

Supplemental Content

Support Center